The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Angel
I have added another 50,000 shares this week to bring my holdings to 100,000 .
Karuna is a jewel in the crown once the FDA approves its blockbuster Schizophrenia drug, releasing another $400m from the royalties buyer, milestone payments as well as its 2.8% equity stake which could be worth c$250m. Vedanta could be the next major winner and backed by Pfizer and the likes of the Gates Foundation and where Puretech has a 48% equity stake and royalties etc.
Reading the last RNS update you will note Puretech is to announce major news soon on capital allocation and perhaps establishing new Foundation companies for its own in house drug therapies with a major return via a special dividend to shareholders hinted at.
Zohar is consulting with major shareholders including Invesco who hold 23% of the shares on best strategy on this proposal which could be announced at the fire side conferences in 2/3 weeks.
Interesting few weeks ahead
Dyor
ATB
Pokerchips
Agreed
If there is an issue with Alora/Avion then Immupharma must inform the market immediately.
Anyway I have an order to buy 500,000 at 1.75p since 10am which would bring my total holdings to 3m.
Not been filled as yet.
Having witnessed the unbelievable events in Ethernity over the past week where the SP moved from .25p to 4.7p today , a rise of c4.5p or 1,800% , here's hoping the Tiktok herd discover Immupharma!!!
Lambo
The AIM market is the wild West at the moment with most companies struggling to get funding and being totally ignored by investors particularly minnows like Immupharma whose historic performance has been dreadful.
However the company is on the cusp of being a serious player with its late stage drug therapies and should the Avion commitment be confirmed and trial dates confirmed the share price could rerate sharply.
If a Rest of the World deal on Lupuzor or anything on CIPD be announced it would be even better.
I have an investment in Ethernity Networks of a similar amount to Immupharma which was awful until this week a rerating took place and the shares surged over 2 days by a staggering 1600% at one stage yesterday with some profit taking today.
The volumes traded were twice the issued shares as the punters piled in.
I am not saying for one minute that this will happen in Immupharma's case but it illustrates how beaten down AIM stocks can bolt ahead if the herd smells something.
Dream on you rightly say but Immupharma will rerate substantially on some good news imho.
Lambo
Let's assume Alora/Avion walk after exhaustive consultations with the FDA which resulted in a comprehensive set of guidelines and parameters in relation to the Phase 2/3 Lupuzor trials and after Alora
invested c£1.1 m directly in Immupharma and thereby relinquish its rights to North American Market for Lupuzor.
Then Immupharma would be free to discuss a deal with a large Pharma for the total worldwide rights for Lupuzor and for CIPD.
Immupharma may also then be an attractive takeover target given its tiny market cap of c£6m.
I don't think Art Deas has come this far to walk away but it is possible but would not be fatal for Immupharma imho.
If Alora/Avion has walked Immupharma must issue a RNS asap and so far we haven't seen one.
I agree the silence is extremely unsettling but as someone who has been here for 8 years, I am used to it.
Nolupus
No
Alora Pharma Group only mentions drugs and therapies it actually sells and distributes not a drug which has yet to be approved or in clinical trials.
I hope that is of assistance to you.
Also as a private company it has no regulatory or other
requirement to say anything to anyone.
Cheers
Just to add that the Alora Group has 90 + drug therapies on the market at present in 7 major therapeutics.
The Alora new website has only come on stream in the past 2 months.
I urge investors to access it now.
Oscar
I will not go through again my previous detailed analysis of the Alora Pharma Group other than to advise investors to go the updated Alora website to get a full picture of this growing private Pharmaceuticals enterprise with 5 major subsidiary companies including Avion Pharma who in 2022 got FDA approval for Dhivy a drug to treat Parkinsons Disease.
The Alora Group headed by Art Deas with 5 manufacturing and research facilities mainly based in Georgia, USA with 600 employees and a large range
of diverse drugs and therapies is possibly valued at over $1billion.
It's acquisition of Osmotica's manufacturing facilities
and drug therapies for over $200m in 2022 was a big statement.
I agree with you that Lupuzor is a big deal for Art Deas for relatively small money and he has gone so far now he will see this through.
The AIM market is a hellhole for investors at the moment but Immupharma could be a absolute gem in the manure .
Dyor
Atb
Oscar
Many thanks for your usual well informed and intelligent posts.
It is appreciated.
The markets are awful at the moment with the Israeli horror show adding more concern and trepidation.
Provided there is no serious escalation the markets will adjust. If there is a World War 3 then Immupharma will be the least of our worries.
Also if the Alora/Avion deal, which is a legal commitment signed by both parties, is in dispute or difficulty then Immupharma must notify the market immediately.
Even if Art Deas walks, there will plenty more interest from other Pharmas given the extensive consultation with the FDA on the trial parameters and the FDA 's subsequent guidance.
We are still in the game imho.
LearningG
Thank you for your vote of confidence in me being Chairman of Ethernity.
However some would question my judgement in building up a large stake in the first place and not selling at a large profit when the SP hit 55/60p ( albeit briefly) and they would be correct with the benefit of hindsight.
However hindsight is wonderful but a lot happened subsequent to my initial investments in Ethernity in 2019/20 with the total pandemic lockdowns in Israel in
particular , hundreds of Hamas rockets landing in Lot close to Ethernity old HQ, followed by the Ukraine war , major chip shortages and delays in 5G and other telecom infrastructure investment and the crash in Technology companies share prices in 2022 et al.
Don't get me wrong Ethernity management and the Board made some horrible mistakes with over optimistic forecasts, bad financial management , major R&D spend on new products and IP linked to misguided contracts with OEMs which were totally dependent on successful deployment of the OEMs roll outs and leaving Ethernity exposed to cancellations, delays and in some cases non payment etc.
They have expended cash and resources in product development and now are cash strapped as it changes back to a licencing model .
It appears too late but I have proposed possible solutions to David Levi involving an angel investor using a Senior Unsecured Convertible Loan Note structure and an amendment to the Subscription Agreement whereby the new investor and Bergen could exercise their respective rights at the warrants price of 6p and perhaps give the Convertible Loan Note holder warrants on a 1 to 1 basis on the amount of the Note.
I am proposing a CLN of c$1m Convertible at 6p with a coupon of say 5% ranking ahead of the equity and a similar amount in warrants.
This is a deal that could sort Bergen out , get cash in now and warrants cash subsequently.
However I suspect Ethernity need to show new contracts before such a deal can be done and get the SP back to 3/5p.
It is possible but a may be very late in the day.
There are 30 + billionaires in Israel and surely Levi/ Yosi and the other Israeli Directors have still some friends.
At the moment all is lost but there are solutions I hope
01234
I don't think I was positive just a massive exhalation of relief that the RNS was concerning liquidation, delisting, Directors resignations etc.
Ethernity has still to perform a minor miracle if it is to survive and has just 3/4 months to do so.
Cash position is the key consideration now for both customers and investors.
Ethernity has been working with Raytheon Technologies on the aviation switch software deal for over 4 years and finally the US Government has approved Raytheon to deal with Ethernity.
That is a very attractive piece of US Government approved business and indeed could be important to an acquirer not to mention Ethernity's near $40m in tax losses.
Another possible gold nugget in the manure is the confirmation that the US Government has approved the US Tier 1 military giant ( which Levy already mentioned previously as Raytheon Technologies) to work with Ethernity on a longstanding aviation software product deal.
This could be significant IF it comes to fruition.
It looks like the SP is stable after results and may even go higher during the day.
A big few weeks ahead but not in liquidation yet!
I will review Interims in detail later but , given that I thought the company was going to go bust this week , I now feel it has a fighting chance .
The key is the next few weeks to see whether there is any positive newsflow.
If not then we are in trouble.
ATB
And Ethernity received the last cash tranche of 60% of the Tarana order of $1.5m I.e. $900,000 two weeks ago.
Not as bad as I was expecting but Ethernity still need licencing contracts ASAP to generate the cash flow to get to EBITDA positive for 2nd half.
Not dead yet but we need a major boost from somewhere.
Skid
Not to mention the Indian contract which Levi said would grow to 10s of millions of $ in revenue at our meeting in London and was never heard of again.
There were so other many false statements and forecasts made since 2020 , non of which ever materialised.
Even the burger van revenues reported were not real with most ending up in debtors or written off.
It was a fantasy business with nothing ever produced that anyone ever wanted apart from low tech stuff supplied to Tarana who themselves are struggling to produce revenues of any substance.
Sad denouement for us all after a long 4/5 years of believing in this gang of chancers.